Key facts
- Notable investors include Cville BioHub, New Dominion Angels.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Built Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Built Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Built Biotechnologies
Operator of a biotechnology company designed for research and biomanufacturing of genetic engineering materials. The company includes assembly of high-fidelity (DNA) deoxyribonucleic acid constructs, production of clonal plasmid materials, synthesis of linear deoxyribonucleic acid fragments, preparation of pooled plasmid libraries, and maintenance of a validated inventory of modular components, enabling biotechnology, pharmaceutical, and academic research markets to obtain complex and precise genetic constructs, reduce in-house assembly time, support experimental workflows, and advance development activities that depend on reliable and customizable deoxyribonucleic acid materials.
- Sector
- Healthcare
- HQ
- Charlottesville, VA, United States
- Founded
- 2023
- Employees
- 8
- Website
- builtdna.com/
- Ownership
- Privately Held (backing)
Built Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Built Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Built Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.